WO2008124165A9 - Self-assembling nanoparticle drug delivery system - Google Patents

Self-assembling nanoparticle drug delivery system Download PDF

Info

Publication number
WO2008124165A9
WO2008124165A9 PCT/US2008/004585 US2008004585W WO2008124165A9 WO 2008124165 A9 WO2008124165 A9 WO 2008124165A9 US 2008004585 W US2008004585 W US 2008004585W WO 2008124165 A9 WO2008124165 A9 WO 2008124165A9
Authority
WO
WIPO (PCT)
Prior art keywords
self
delivery system
drug delivery
nanoparticle drug
assembling nanoparticle
Prior art date
Application number
PCT/US2008/004585
Other languages
French (fr)
Other versions
WO2008124165A2 (en
WO2008124165A3 (en
Inventor
Los Rios Miguel A De
Kenneth J Oh
Timothy L Bullock
Patrick T Johnson
Jacek Ostrowski
Original Assignee
Chimeros Inc
Los Rios Miguel A De
Kenneth J Oh
Timothy L Bullock
Patrick T Johnson
Jacek Ostrowski
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Chimeros Inc, Los Rios Miguel A De, Kenneth J Oh, Timothy L Bullock, Patrick T Johnson, Jacek Ostrowski filed Critical Chimeros Inc
Priority to EP08742685A priority Critical patent/EP2134740A2/en
Priority to CA002683063A priority patent/CA2683063A1/en
Priority to AU2008236566A priority patent/AU2008236566A1/en
Publication of WO2008124165A2 publication Critical patent/WO2008124165A2/en
Publication of WO2008124165A3 publication Critical patent/WO2008124165A3/en
Publication of WO2008124165A9 publication Critical patent/WO2008124165A9/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51—Nanocapsules; Nanoparticles
    • A61K9/5107—Excipients; Inactive ingredients
    • A61K9/5176—Compounds of unknown constitution, e.g. material from plants or animals
    • A61K9/5184—Virus capsids or envelopes enclosing drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51—Nanocapsules; Nanoparticles
    • A61K9/5107—Excipients; Inactive ingredients
    • A61K9/513—Organic macromolecular compounds; Dendrimers
    • A61K9/5169—Proteins, e.g. albumin, gelatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6901—Conjugates being cells, cell fragments, viruses, ghosts, red blood cells or viral vectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6921—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere
    • A61K47/6925—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being a microcapsule, nanocapsule, microbubble or nanobubble
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5089—Processes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B82—NANOTECHNOLOGY
    • B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
    • B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
    • C12N15/88—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation using microencapsulation, e.g. using amphiphile liposome vesicle
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2730/00—Reverse transcribing DNA viruses
    • C12N2730/00011—Details
    • C12N2730/10011—Hepadnaviridae
    • C12N2730/10111—Orthohepadnavirus, e.g. hepatitis B virus
    • C12N2730/10122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes

Abstract

A self-assembling nanoparticle drug delivery system for the delivery of various bioactive agents including peptides, proteins, nucleic acids or synthetic chemical drugs is provided. The self-assembling nanoparticle drug delivery system described herein includes viral capsid proteins, such as Hepatitis B Virus core protein, encapsulating the bioactive agent, a lipid layer or lipid/cholesterol layer coat and targeting or facilitating molecules anchored in the lipid layer. A method for construction of the self-assembling nanoparticle drug delivery system is also provided.
PCT/US2008/004585 2007-04-09 2008-04-09 Self-assembling nanoparticle drug delivery system WO2008124165A2 (en)

Priority Applications (3)

Application Number Priority Date Filing Date Title
EP08742685A EP2134740A2 (en) 2007-04-09 2008-04-09 Self-assembling nanoparticle drug delivery system
CA002683063A CA2683063A1 (en) 2007-04-09 2008-04-09 Self-assembling nanoparticle drug delivery system
AU2008236566A AU2008236566A1 (en) 2007-04-09 2008-04-09 Self-assembling nanoparticle drug delivery system

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US91070407P 2007-04-09 2007-04-09
US60/910,704 2007-04-09

Publications (3)

Publication Number Publication Date
WO2008124165A2 WO2008124165A2 (en) 2008-10-16
WO2008124165A3 WO2008124165A3 (en) 2008-12-04
WO2008124165A9 true WO2008124165A9 (en) 2009-04-30

Family

ID=39730629

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2008/004585 WO2008124165A2 (en) 2007-04-09 2008-04-09 Self-assembling nanoparticle drug delivery system

Country Status (5)

Country Link
US (2) US20090226525A1 (en)
EP (1) EP2134740A2 (en)
AU (1) AU2008236566A1 (en)
CA (1) CA2683063A1 (en)
WO (1) WO2008124165A2 (en)

Families Citing this family (66)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1773303A2 (en) * 2004-05-25 2007-04-18 Chimeracore, Inc. Self-assembling nanoparticle drug delivery system
DE602007005366D1 (en) * 2006-04-07 2010-04-29 Chimeros Inc COMPOSITIONS AND METHOD FOR THE TREATMENT OF B-CELL MALIGNOMES
AU2007283022B2 (en) 2006-08-08 2011-07-28 Rheinische Friedrich-Wilhelms-Universitat Bonn Structure and use of 5' phosphate oligonucleotides
EP2170267A4 (en) * 2007-06-28 2011-04-27 Agency Science Tech & Res Cationic peptide for delivering an agent into a cell
EP2036980A1 (en) 2007-09-14 2009-03-18 Gruber, Jens Down regulation of gene expression using virus-like particles charged with nucleic acid
WO2009141146A1 (en) 2008-05-21 2009-11-26 Gunther Hartmann 5' triphosphate oligonucleotide with blunt end and uses thereof
WO2010042751A2 (en) * 2008-10-08 2010-04-15 Chimeros Inc. Chimeric therapeutics, compositions, and methods for using same
WO2010120874A2 (en) * 2009-04-14 2010-10-21 Chimeros, Inc. Chimeric therapeutics, compositions, and methods for using same
AU2010254549B2 (en) 2009-05-27 2016-10-20 Selecta Biosciences, Inc. Nanocarriers possessing components with different rates of release
WO2011017835A1 (en) 2009-08-11 2011-02-17 Nanjing University Preparation method of protein or peptide nanoparticles for in vivo drug delivery by unfolding and refolding
MX2012013713A (en) 2010-05-26 2013-01-28 Selecta Biosciences Inc Nanocarrier compositions with uncoupled adjuvant.
CN103202812B (en) * 2010-08-09 2015-10-28 南京大学 A kind of method of protein nano grain for the preparation of sending pharmacological active substance in body
US20130295012A1 (en) 2010-08-30 2013-11-07 President And Fellows Of Harvard College Shear controlled release for stenotic lesions and thrombolytic therapies
EP2508530A1 (en) 2011-03-28 2012-10-10 Rheinische Friedrich-Wilhelms-Universität Bonn Purification of triphosphorylated oligonucleotides using capture tags
CN113018452A (en) 2011-04-29 2021-06-25 西莱克塔生物科技公司 Tolerogenic synthetic nanocarriers for antigen-specific deletion of effector T cells
EA201490381A1 (en) 2011-07-29 2014-06-30 Селекта Байосайенсиз, Инк. SYNTHETIC NANOSEAGES WHICH STIMULATE THE FORMATION OF HUMORAL IMMUNE RESPONSE AND IMMUNE RESPONSE MEDIATED BY CYTOTOXIC T-LYMPHOCYTES (CTL)
WO2013036973A2 (en) * 2011-09-09 2013-03-14 Biomed Realty, L.P. Methods and compositions for controlling assembly of viral proteins
US11523990B2 (en) 2012-09-13 2022-12-13 Denovomatrix Gmbh Non-covalent, self-organzing hydrogel matrix for biotechnological applications
DE102012108560B4 (en) * 2012-09-13 2018-12-20 Leibniz-Institut Für Polymerforschung Dresden E.V. Noncovalent self-assembling hydrogel matrix for biotechnological applications
EP2712870A1 (en) 2012-09-27 2014-04-02 Rheinische Friedrich-Wilhelms-Universität Bonn Novel RIG-I ligands and methods for producing them
US10035990B2 (en) 2012-12-12 2018-07-31 Agency For Science, Technology, And Research Specific internalization of nanoparticles into protein cages
WO2014145205A2 (en) 2013-03-15 2014-09-18 St. Jude Children's Research Hospital Methods and compositions of p27kip1 transcription modulators
CA2910575C (en) 2013-05-03 2023-10-24 Selecta Biosciences, Inc. Tolerogenic synthetic nanocarriers and therapeutic macromolecules for reduced or enhanced pharmacodynamic effects
EA201592273A1 (en) 2013-06-04 2016-09-30 Селекта Байосайенсиз, Инк. REPEATED INTRODUCTION OF NON-IMMUNOSUPRESSIVE ANTIGENSPECIFIC IMMUNOTHERAPY
EP3049154B1 (en) 2013-09-29 2019-11-13 St. Jude Children's Research Hospital, Inc. Aryl substituted aminomethyl spectinomycin analogs as antibacterial agents
US20150374815A1 (en) 2014-06-25 2015-12-31 Selecta Biosciences, Inc. Methods and compositions for treatment with synthetic nanocarriers and immune checkpoint inhibitors
US10029012B2 (en) * 2014-09-05 2018-07-24 University Of Pittsuburgh—Of The Commonwealth System Of Higher Education Peptide-mediated intravesical delivery of therapeutic and diagnostic agents
IL292577A (en) 2014-09-07 2022-06-01 Selecta Biosciences Inc Methods and compositions for attenuating gene editing anti-viral transfer vector immune responses
KR101734308B1 (en) 2015-01-21 2017-05-12 한국과학기술연구원 RNA/DNA hybrid nanoparticle used for target-specific siRNA delivery and use thereof
JP6902025B2 (en) 2015-06-18 2021-07-14 ティン セラピューティックス エルエルシー Methods and compositions for the prevention and treatment of hearing loss
AU2016296592B2 (en) 2015-07-17 2021-08-19 Arcturus Therapeutics, Inc. Compositions and agents against Hepatitis B virus and uses thereof
US20170137821A1 (en) 2015-07-17 2017-05-18 Arcturus Therapeutics, Inc. Molecules and agents for treating hepatitis b virus
WO2017096262A1 (en) 2015-12-04 2017-06-08 Jomoco, Corp. Compositions and methods to mitigate or prevent an immune response to an immunogenic therapeutic molecule in non-human primates
CN108602849B (en) * 2016-04-06 2022-10-21 俄亥俄州国家创新基金会 RNA ligand-displaying exosomes for specific delivery of therapeutic agents to cells by RNA nanotechnology
US20200208157A1 (en) * 2016-04-06 2020-07-02 Ohio State Innovation Foundation Rna ligand-displaying exosomes for specific delivery of therapeutics to cell by rna nanotechnology
EP4014967A1 (en) 2016-04-29 2022-06-22 Icahn School of Medicine at Mount Sinai Targeting the innate immunesystem to induce long-term tolerance and to resolve macrophage accumulation in atherosclerosis
US20180085319A1 (en) 2016-09-27 2018-03-29 Takashi Kei Kishimoto Methods and compositions for treating cancer
AU2018205496A1 (en) 2017-01-07 2019-07-25 Selecta Biosciences, Inc. Patterned dosing of immunosuppressants coupled to synthetic nanocarriers
BR112019018748A2 (en) 2017-03-11 2020-04-07 Selecta Biosciences Inc methods and compositions related to combined treatment with anti-inflammatories and synthetic nanocarriers comprising an immunosuppressant
EP3395327B1 (en) 2017-04-28 2020-03-11 denovoMATRIX GmbH Non-covalently assembled conductive hydrogel
CN107286249A (en) * 2017-06-07 2017-10-24 中国药科大学 A kind of restructuring apoferritin nanocages of oligomerization polylysine modification and its preparation
EP3415165A1 (en) 2017-06-16 2018-12-19 Technische Universität Dresden Non-covalently assembled biomatrix layer
BR112020007157A2 (en) 2017-10-13 2020-09-24 Selecta Biosciences, Inc. methods and compositions for the attenuation of viral transfer anti-vector igm responses
MX2021000637A (en) 2018-07-16 2021-06-23 Selecta Biosciences Inc Methods and compositions of otc constructs and vectors.
US20200038463A1 (en) 2018-07-16 2020-02-06 Selecta Biosciences, Inc. Methods and compositions of mma constructs and vectors
EP3911663A4 (en) * 2018-12-28 2022-09-28 The Board Of Trustees Of The Leland Stanford Junior University Engineered hepatitis b core polypeptide
BR112021021566A2 (en) 2019-04-28 2022-04-19 Selecta Biosciences Inc Methods for treating individuals with preexisting immunity to viral transfer vectors
CN114206396A (en) 2019-05-28 2022-03-18 西莱克塔生物科技公司 Methods and compositions for attenuating an immune response against an antiviral transfer vector
CN110974806B (en) * 2019-12-27 2021-05-04 中山大学 Amphiphilic nano cage with active oxygen sensitivity and preparation method and application thereof
EP4103160A1 (en) * 2020-02-13 2022-12-21 ETH Zurich Nanoparticles encapsulating small molecules
CN111349149A (en) * 2020-03-17 2020-06-30 中国科学院苏州纳米技术与纳米仿生研究所 Tobacco mosaic virus capsid protein mutant and application thereof
EP4221685A1 (en) 2020-09-29 2023-08-09 Oxford University Innovation Limited Stroke treatment
WO2022150335A1 (en) 2021-01-05 2022-07-14 Selecta Biosciences, Inc. Viral vector dosing protocols
BR112023018950A2 (en) 2021-03-19 2024-02-27 Icahn School Med Mount Sinai COMPOUND, NANOBIOLOGICAL AND PHARMACEUTICAL COMPOSITIONS, METHODS FOR TREATING A CELL PROLIFERATION DISORDER, FOR TREATING SEPSIS AND FOR ACTIVATING A NOD2 RECEPTOR, PROCESS FOR MANUFACTURING A NANOBIOLOGICAL COMPOSITION AND KIT
US20220323607A1 (en) 2021-04-09 2022-10-13 Selecta Biosciences, Inc. Synthetic nanocarriers comprising an immunosuppressant in combination with high affinity il-2 receptor agonists to enhance immune tolerance
WO2023064367A1 (en) 2021-10-12 2023-04-20 Selecta Biosciences, Inc. Methods and compositions for attenuating anti-viral transfer vector igm responses
US20230140196A1 (en) 2021-10-12 2023-05-04 Selecta Biosciences, Inc. Viral vector dosing protocols
WO2023086615A1 (en) 2021-11-14 2023-05-19 Selecta Biosciences, Inc. Multiple dosing with viral vectors
CN114107397A (en) * 2021-11-19 2022-03-01 深圳市大鳄生物科技股份有限公司 Delivery system, complex and drug for delivering negatively charged nucleic acids
US20230263906A1 (en) 2022-01-10 2023-08-24 Selecta Biosciences, Inc. High affinity il-2 receptor agonists and synthetic nanocarrier dose sparing
WO2023172624A1 (en) 2022-03-09 2023-09-14 Selecta Biosciences, Inc. Immunosuppressants in combination with anti-igm agents and related dosing
US20230322884A1 (en) 2022-03-09 2023-10-12 Selecta Biosciences, Inc. Immunosuppressant in combination with high affinity il-2 receptor agonists and related dosing
WO2023183568A1 (en) 2022-03-25 2023-09-28 Selecta Biosciences, Inc. Synthetic nanocarriers comprising an immunosuppressant in combination with high affinity il-2 receptor agonists and anti-igm agents
WO2023196566A1 (en) 2022-04-08 2023-10-12 Selecta Biosciences, Inc. High affinity il-2 receptor agonists and immunosuppressants to enhance immune tolerance
WO2023225503A2 (en) * 2022-05-16 2023-11-23 Dairy Management Inc. Protein particles including an active agent and methods of making and using the same
CN116212042B (en) * 2023-03-10 2023-09-05 中国人民解放军空军军医大学 RNA-loaded brain delivery system and preparation method thereof

Family Cites Families (52)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4816564A (en) * 1986-01-31 1989-03-28 Merck & Co., Inc. Method for producing hepatitis B virus proteins in yeast
NZ228948A (en) * 1988-05-13 1991-06-25 Phillips Petroleum Co Hbv particles containing s and pre-s 2 proteins and recombinant processes for their production in yeast cells
WO1992003537A1 (en) * 1990-08-15 1992-03-05 Therion Biologics Corporation Self-assembling replication defective hybrid virus particles
WO1993000103A1 (en) * 1991-06-21 1993-01-07 The Wistar Institute Of Anatomy And Biology Chimeric envelope proteins for viral targeting
US6749868B1 (en) * 1993-02-22 2004-06-15 American Bioscience, Inc. Protein stabilized pharmacologically active agents, methods for the preparation thereof and methods for the use thereof
US6537579B1 (en) * 1993-02-22 2003-03-25 American Bioscience, Inc. Compositions and methods for administration of pharmacologically active compounds
US6753006B1 (en) * 1993-02-22 2004-06-22 American Bioscience, Inc. Paclitaxel-containing formulations
US5439686A (en) * 1993-02-22 1995-08-08 Vivorx Pharmaceuticals, Inc. Methods for in vivo delivery of substantially water insoluble pharmacologically active agents and compositions useful therefor
DE69433723T3 (en) * 1993-02-22 2008-10-30 Abraxis Bioscience, Inc., Los Angeles PROCESS FOR IN VIVO ADMINISTRATION OF BIOLOGICAL SUBSTANCES AND COMPOSITIONS USED THEREFROM
US6096331A (en) * 1993-02-22 2000-08-01 Vivorx Pharmaceuticals, Inc. Methods and compositions useful for administration of chemotherapeutic agents
EP0804249A2 (en) * 1994-03-15 1997-11-05 Brown University Research Foundation Polymeric gene delivery system
US6204059B1 (en) * 1994-06-30 2001-03-20 University Of Pittsburgh AAV capsid vehicles for molecular transfer
US6613749B1 (en) * 1994-07-26 2003-09-02 Imperial College Innovations Limited Papovavirus pseudocapsids and use thereof for exogenous material transfer
US7422902B1 (en) * 1995-06-07 2008-09-09 The University Of British Columbia Lipid-nucleic acid particles prepared via a hydrophobic lipid-nucleic acid complex intermediate and use for gene transfer
ATE278794T1 (en) * 1995-06-15 2004-10-15 Crucell Holland Bv PACKAGING SYSTEMS FOR HUMAN, HUMAN ADENOVIRUSES, FOR USE IN GENE THERAPY
US6284494B1 (en) * 1995-12-12 2001-09-04 The University Of British Columbia Methods and compositions for synthesis of oligosaccharides using mutant glycosidase enzymes
US6063370A (en) * 1996-04-05 2000-05-16 The Board Of Trustees Of The University Of Illinois Macromolecular complexes for drug delivery
FR2749323B1 (en) * 1996-06-04 1998-07-10 Pasteur Merieux Serums Vacc PSEUDO-PARTICLES VIRALES USEFUL AS A VECTOR OF NUCLEIC ACID DELIVERY
WO1998011916A1 (en) * 1996-09-18 1998-03-26 The Board Of Regents Of The University Of Texas System Viral defective interfering particles and uses thereof
AU738585B2 (en) * 1996-11-08 2001-09-20 Government Of The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services, The Synthesis and purification of hepatitis C virus-like particles
US6180389B1 (en) * 1997-01-03 2001-01-30 The Research And Development Institute, Inc. Virion-constrained nanoparticles comprising a plant virion coat protein shell and encapsulated guest molecules
US6506559B1 (en) * 1997-12-23 2003-01-14 Carnegie Institute Of Washington Genetic inhibition by double-stranded RNA
US6231864B1 (en) * 1998-02-12 2001-05-15 Immune Complex Corporation Strategically modified hepatitis B core proteins and their derivatives
WO2002007774A2 (en) * 2000-07-19 2002-01-31 The Regents Of The University Of California Methods for therapy of neurodegenerative disease of the brain
WO2000008654A1 (en) * 1998-08-05 2000-02-17 Sony Corporation Composition for electrolyte, electrolyte and process for producing the same, and cell containing the same
US6759237B1 (en) * 1998-11-05 2004-07-06 The Trustees Of The University Of Pennsylvania Adeno-associated virus serotype 1 nucleic acid sequences, vectors and host cells containing same
IL143475A0 (en) * 1998-12-04 2002-04-21 Biogen Inc Hepatitis b virus core antigen particles and vaccines and pharmaceutical compositions containing the same
US6710173B1 (en) * 1999-06-25 2004-03-23 Progenics Pharmaceuticals, Inc. Stabilized viral envelope proteins and uses thereof
US6593308B2 (en) * 1999-12-03 2003-07-15 The Regents Of The University Of California Targeted drug delivery with a hyaluronan ligand
US6602932B2 (en) * 1999-12-15 2003-08-05 North Carolina State University Nanoparticle composites and nanocapsules for guest encapsulation and methods for synthesizing same
US6616944B2 (en) * 2000-03-08 2003-09-09 Medinnova Gesellschaft Fur Medizinsche Innovationen Aus Adkademischer Forschung Mbh Self-assembling colloidal carriers for protein delivery
US7332337B2 (en) * 2000-05-16 2008-02-19 Galapagos Nv Viral vectors having tissue tropism for T-lymphocytes, B- and mast cells
US6696038B1 (en) * 2000-09-14 2004-02-24 Expression Genetics, Inc. Cationic lipopolymer as biocompatible gene delivery agent
US20040259247A1 (en) * 2000-12-01 2004-12-23 Thomas Tuschl Rna interference mediating small rna molecules
AU2002322285A1 (en) * 2001-06-22 2003-01-08 The Trustees Of The University Of Pennsylvania Method for rapid screening of bacterial transformants and novel simian adenovirus proteins
US7101995B2 (en) * 2001-08-27 2006-09-05 Mirus Bio Corporation Compositions and processes using siRNA, amphipathic compounds and polycations
US20050089526A1 (en) * 2001-09-06 2005-04-28 Moore John P. Human immunodeficiency virus envelope clycoprotein mutants and uses thereof
EP2301582B1 (en) * 2001-11-21 2017-07-12 The Trustees Of The University Of Pennsylvania Simian adenovirus nucleic acid and amino acid sequences, vectors containing same, and methods of use
DK2359869T3 (en) * 2001-12-17 2019-04-15 Univ Pennsylvania Sequences of adeno-associated virus (AAV) serotype 8, vectors containing these, and uses thereof
DE60335186D1 (en) * 2002-06-20 2011-01-13 Cytos Biotechnology Ag PACKAGED VIRUS PARTICLES IN COMBINATION WITH CPG FOR USE AS ADJUVANTIES WITH ALLERGENS. MANUFACTURING METHOD AND USE
US7148342B2 (en) * 2002-07-24 2006-12-12 The Trustees Of The University Of Pennyslvania Compositions and methods for sirna inhibition of angiogenesis
AU2003287526A1 (en) * 2002-11-06 2004-06-03 Protein-stabilized liposomal formulations of pharmaceutical agents
JP2004175665A (en) * 2002-11-22 2004-06-24 Japan Science & Technology Agency Protein hollow nanoparticle and drug using the same
DK1585548T3 (en) * 2002-12-09 2018-09-03 Abraxis Bioscience Llc COMPOSITIONS AND PROCEDURES FOR THE DELIVERY OF PHARMACOLOGICAL AGENTS
AU2004282563A1 (en) * 2003-10-15 2005-04-28 Board Of Regents, The University Of Texas System Viral fibers
EP1773303A2 (en) * 2004-05-25 2007-04-18 Chimeracore, Inc. Self-assembling nanoparticle drug delivery system
CA2572129A1 (en) * 2004-07-01 2006-01-12 The Circle For The Promotion Of Science And Engineering Viral particle-like construct and method of forming the same under physiological conditions
GB0416487D0 (en) * 2004-07-23 2004-08-25 Isis Innovation Modified virus
CN101056539B (en) * 2004-09-09 2012-12-12 综合医院公司 Modulating phosphatase activity in cardiac cells
EP1799251A2 (en) * 2004-09-17 2007-06-27 Chr. Hansen A/S Chimeric phage-derived particles, methods for their production and use
US20070258889A1 (en) * 2005-11-09 2007-11-08 Montana State University Novel nanoparticles and use thereof
DE602007005366D1 (en) * 2006-04-07 2010-04-29 Chimeros Inc COMPOSITIONS AND METHOD FOR THE TREATMENT OF B-CELL MALIGNOMES

Also Published As

Publication number Publication date
EP2134740A2 (en) 2009-12-23
AU2008236566A1 (en) 2008-10-16
WO2008124165A2 (en) 2008-10-16
US20140010885A1 (en) 2014-01-09
US20090226525A1 (en) 2009-09-10
WO2008124165A3 (en) 2008-12-04
CA2683063A1 (en) 2008-10-16

Similar Documents

Publication Publication Date Title
WO2008124165A3 (en) Self-assembling nanoparticle drug delivery system
WO2006033679A3 (en) Self-assembling nanoparticle drug delivery system
Yan et al. Non-viral vectors for RNA delivery
Wolfram et al. Clinical cancer nanomedicine
Lin et al. Biological characteristics of exosomes and genetically engineered exosomes for the targeted delivery of therapeutic agents
US20170232115A1 (en) Porous nanoparticle-supported lipid bilayers (protocells) for targeted delivery including transdermal delivery of cargo and methods thereof
Reichmuth et al. mRNA vaccine delivery using lipid nanoparticles
Mastrobattista et al. Artificial viruses: a nanotechnological approach to gene delivery
Saurer et al. Layer-by-layer assembly of DNA-and protein-containing films on microneedles for drug delivery to the skin
Gote et al. A comprehensive review of mRNA vaccines
Wagner Programmed drug delivery: nanosystems for tumor targeting
Somiya et al. Current progress of virus-mimicking nanocarriers for drug delivery
JP2014532071A5 (en)
WO2005112886A3 (en) Methods and articles for the delivery of therapeutic agents
Song et al. Design and development of nanomaterial-based drug carriers to overcome the blood–brain barrier by using different transport mechanisms
RU2008140370A (en) NANOPARTICLES FILLED WITH ACTIVE SUBSTANCE ON THE BASIS OF HYDROPHILIC PROTEINS
Gabathuler Development of new peptide vectors for the transport of therapeutic across the blood–brain barrier
Somiya et al. Intracellular trafficking of bio-nanocapsule–liposome complex: Identification of fusogenic activity in the pre-S1 region of hepatitis B virus surface antigen L protein
Cheng et al. Nanomaterial-based drug delivery system targeting lymph nodes
Nafee et al. Nucleic acids-based nanotherapeutics crossing the blood brain barrier
Ghorai et al. Cell-Penetrating and Targeted Peptides Delivery Systems as Potential Pharmaceutical Carriers for Enhanced Delivery across the Blood–Brain Barrier (BBB)
Niculescu et al. New applications of lipid and polymer-based nanoparticles for nucleic acids delivery
Kasina et al. Nanoparticle delivery systems for substance use disorder
Nordling‐David et al. Gene delivery by liposomes
Della Pelle et al. Nucleic acid delivery with red-blood-cell-based carriers

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 08742685

Country of ref document: EP

Kind code of ref document: A2

ENP Entry into the national phase

Ref document number: 2683063

Country of ref document: CA

NENP Non-entry into the national phase

Ref country code: DE

WWE Wipo information: entry into national phase

Ref document number: 2008236566

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: 2008742685

Country of ref document: EP

ENP Entry into the national phase

Ref document number: 2008236566

Country of ref document: AU

Date of ref document: 20080409

Kind code of ref document: A